IL-1-receptor Antagonist During Cephalic Phase of Insulin Secretion in Health and Type 2 Diabetes

Inclusion criteria: Main inclusion criteria: * Age ≥ 18 years and ≤ 70 years at screening * Male or female of non-child-bearing potential (meaning for women: not currently pregnant, post-menopausal female or using condoms and either intrauterine devices or 3-monthly contraceptive injection or birth-control pill.) Healthy subjects: * No apparent disease requiring medication * BMI \< 25 kg/ m2 * C-reactive protein ≤ 2 mg/L Obese diabetic type 2 subjects: * Type 2 diabetes * HbA1c 7.0 -10.0% * BMI ≥ 30.0 kg/m2 * C-reactive protein ≥ 2 mg/L Exclusion criteria: Subjects will be excluded from the study if they meet any of the following criteria: * Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation * Aversion or allergy to paracetamol or any component of the meal. * Known history of allergy or hypersensitivity to any component of the investigational product formulations * Concomitant treatment with GLP-1 agonists, DPP-4 inhibitors, insulin or insulin derivative * Change in diabetes medication within the last 30 days * Any biologic drugs targeting the immune system * Fever, or other signs of infection requiring antibiotics within 3 weeks prior to screening, history of recurrent infection, immunodeficiency, known HIV or tuberculosis infection, active foot ulcer * Participation in another study with investigational drug within 30 days prior to Screening and during the present study * eGFR \< 30 mL/min/1.73m2 per MDRD formula …